Clinical Trial Update: Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 trial update on low-dose recombinant human interleukin-2 in patients recently diagnosed with Type 1 Diabetes; study status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• rhIL-2 (recombinant human interleukin-2) (interleukin-2)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Type 1 Diabetes | Phase 2 | Status: COMPLETED